EOEsther Natalie Oliva

Esther Natalie Oliva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Esther Natalie Oliva has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial

    by Esther N Oliva, Caterina Alati, Valeria Santini, Antonella Poloni, Alfredo Molteni, Pasquale Niscola, Flavia Salvi, Grazia Sanpaolo, Enrico Balleari, Ulrich Germing, et al.


  • Open Access

    Early lenalidomide treatment for low and intermediate‐1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence

    by Esther N. Oliva, Michael Lauseker, Maria Antonietta Aloe Spiriti, Antonella Poloni, Agostino Cortelezzi, Giuseppe A. Palumbo, Enrico Balleari, Grazia Sanpaolo, Antonio Volpe, Alessandra Ricco, et al.

    Lenalidomide is approved for the treatment of transfusion‐dependent (TD) del(5q) myelodysplastic syndromes (MDS). However, few data are available in patients with transfusion‐independent (TI) del(5q) MDS. In the first, observational, part of this 2‐part study, we assessed the impact of transfusion dependence on overall survival (OS) and non‐leukemic death in untreated del(5q) MDS patients who were TD (n = 136), TI with hemoglobin (Hb) ≥10 mg/dL (n = 88), or TI with Hb n = 96). In the second, interventional, part we assessed the quality‐of‐life (QoL) benefits and clinical efficacy of lenalidomide (10 mg/day) in 12 patients with TI del(5q) MDS and Hb R = 0.666, P = 0.035) and fatigue (R = 0.604, P = 0.049) QoL scores. Median physical QoL scores improved significantly after 12 weeks' treatment with lenalidomide (+12.5; P = 0.020). Evaluable TI patients experienced early increases in Hb levels, and all attained an erythroid response. Our findings suggest that TI patients with moderate anemia may benefit from early treatment with lenalidomide.


    • 19 August 2013
      • Vol. 3  (3) , 246-59

    Costs and quality of life in patients with myelodysplastic syndromes.

    by Carlo Lucioni, Carlo Finelli, Silvio Mazzi, Esther N Oliva

    Myelodysplastic syndromes (MDS) encompass a range of myeloid neoplasms characterised by a defect in haematopoietic stem cell maturation, resulting in peripheral cytopenias. As a major consequence, most MDS patients become anaemic, so as to require red blood cell transfusions. To investigate the costs and the impact on quality of life (QOL) of MDS-separately in transfusion-independent (TI) and -dependent (TD) patients-a literature search was conducted. From Medline and Embase, 742 studies were identified, of which 17 were considered eligible. Total medical costs per patient/year range from $ 9,840 to $ 19,811 for the TI condition and from $ 29,608 to $ 51,066 in the TD condition, more than doubling when moving from the former condition to the latter. With regard to QOL, in the transition from TI to TD, QOL could be reduced by half depending on the studies. The TD condition negatively impacts on costs and the QOL of patients with MDS. Therapeutic strategies that reduce transfusion dependence may lead to broad benefits for patients and the community.


    • 25 May 2012
      • Vol. 2  (2) , 136-47

    Quality of life and physicians' perception in myelodysplastic syndromes.

    by Esther Natalie Oliva, Carlo Finelli, Valeria Santini, Antonella Poloni, Vincenzo Liso, Daniela Cilloni, Stefana Impera, Adelmo Terenzi, Alessandro Levis, Agostino Cortelezzi, et al.

    To detect factors associated with quality of life (QOL) of patients with myelodysplastic syndrome (MDS) and to compare the MDS patients' self-assessed QOL with that perceived by their physicians. In an observational, non-interventional, prospective, multicentre study, QOL was evaluated in 148 patients with newly diagnosed low- and intermediate-risk IPSS MDS. QOL measures (QOL-E v.2, LASA and EQ-5D) and patient-related candidate determinants of QOL were assessed for up to 18 months. Patients' QOL scores were compared with those obtained by appointed hematologists' assessment and with ECOG performance status (PS). Fatigue was not prevalent at diagnosis, though physical QOL and energy levels were low. Transfusion-dependent patients had worse QOL scores. In multivariate analysis, Hb levels and comorbidities were a major determinant of QOL. Physicians' perception of patients' well-being correlated with patients' QOL. Physicians underestimated the impact of disturbances on patients' QOL, mainly in the MDS-specific components. ECOG PS did not discriminate patients according to QOL status. In conclusion, the association of anemia with QOL is confirmed, while co-morbidities emerge as an independent predictor of QOL in MDS. Fatigue is not a major concern. ECOG PS is not a valuable surrogate of patient's QOL, thus highlighting that physician's judgment of patient's well-being must not substitute patient-reported outcomes. Appropriate questionnaires should be used to assess MDS patients' QOL in order to improve communication and therapeutic choice.


  • Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study

    by Esther Natalie Oliva, Andrea Piccin, Maria Gabriella Mazzucconi, Enrica Morra, Umberto Recine, Enrico Maria Pogliani, Fabrizio Pane, Marco Gobbi, Luigi Gugliotta, Mauro Krampera, et al.

    Essential thrombocythaemia (ET) is a myeloproliferative neoplasm characterized by elevated platelet counts and increased incidence of thrombosis and haemorrhage. Median age at diagnosis is 65–70 years. Life expectancy is similar to that of the healthy population. Symptoms and complications may affect quality of life (QoL); in particular, in elderly patients ET may represent an additional burden. We performed a survey in 494 elderly ET patients to evaluate patient-reported outcomes (PROs). Comorbidities were present in 305 (62%) patients. Factorial analysis based on survey items representing psychological aspects of daily life identified an “attitude domain” with four clusters of patients: (A) very pessimistic (n = 99), (B) pessimistic (n = 101), (C) optimistic (n = 90), and (D) very optimistic (n = 107). Patients in cluster A had more comorbidities (p = 0.003) while patients in cluster D required fewer medical visits and were less disturbed by medications (p < 0.0001). Independent factors predicting Short-Form Health Survey, version 2 physical QoL were grade of optimism (p < 0.0001), gender (p = 0.007), and Charlson comorbidity index (p < 0.0001)). Grade of optimism and disturbances related to medication predicted mental QOL (p < 0.0001). In conclusion, physicians should take into consideration PROs, as “attitude” is associated with physical and mental QoL. Treatment should be tailored to patients’ needs according to comorbidities, lifestyle, and psychological conditions.


  • Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide

    by Massimo Breccia, Laura Cannella, Roberto Latagliata, Mauro Nanni, Michelina Santopietro, Giuseppina Loglisci, Antonietta Ferretti, Rita Barzotti, Esther N. Oliva, Giuliana Alimena


  • Open Access

    Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians

    by E. N. Oliva, F. Nobile, G. Alimena, F. Ronco, G. Specchia, S. Impera, M. Breccia, I. Vincelli, I. Carmosino, P. Guglielmo, et al.

    Background The aim of this study was to evaluate changes in quality of life scores and their association with therapy and survival in unselected elderly patients with acute myeloid leukemia. Design and Methods From February 2003 to February 2007, 113 patients aged more than 60 years with de novo acute myeloid leukemia were enrolled in a prospective observational study. Two different quality of life instruments were employed: the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire – C30 (EORTC QLQ-C30) and a health-related quality of life questionnaire for patients with hematologic diseases (QOL-E). Results Forty-eight patients (42.4%) received intensive chemotherapy and 65 (57.6%) were given palliative treatments. Age greater than 70 years (P=0.007) and concomitant diseases (P=0.019) had a significant impact on treatment allocation. At diagnosis, general quality of life was affected [median QOL-E standardized score 54, interquartile range 46–70; median EORTC global score 50, interquartile range 41–66]. Most patients were given a good ECOG Performance Status (< 2), which did not correlate with the patients’ perception of quality of life. At multivariate analysis, palliative approaches (P=0.016), age more than 70 years (P=0.013) and concomitant diseases (P=0.035) each had an independent negative impact on survival. In a multivariate model corrected for age, concomitant diseases and treatment option, survival was independently predicted by QOL-E functional (P=0.002) and EORTC QLQ-C30 physical function (P=0.030) scores. Conclusions Quality of life could have an important role in elderly acute myeloid leukemia patients at diagnosis as a prognostic factor for survival and a potential factor for treatment decisions.


  • Changes in RPS14 expression levels during lenalidomide treatment in Low‐ and Intermediate‐1‐risk myelodysplastic syndromes with chromosome 5q deletion

    by Esther N. Oliva, Maria Cuzzola, Francesco Nobile, Francesca Ronco, Maria Grazia D’eRrigo, Carmelo Laganà, Fortunato Morabito, Sara Galimberti, Agostino Cortelezzi, Maria A. Aloe Spiriti, et al.

    Background:  Haploinsufficiency of the ribosomal protein S14 RPS14 gene, located in the common deleted region of chromosome 5q, is a potential causal factor of 5q− syndrome. Lenalidomide elicits high response rates and morphological improvements in myelodysplastic syndrome (MDS) patients with chromosome 5q deletion [del(5q)].Methods:  To further evaluate the role of RPS14, its transcription was tested in bone marrow cells from 17 patients with International Prognostic Scoring System defined Low‐ or Intermediate‐1‐risk MDS with del(5q) as a single or additional cytogenetic abnormality receiving treatment with lenalidomide.Results:  After 12 wk of lenalidomide treatment, erythroid responses were observed in all cases with an increase in hemoglobin levels of 2.7 ± 2.5 g/dL (up to a mean 11.8 ± 1.9 g/dL; P = 0.001). Before treatment, RPS14 expression levels were under‐expressed in 15 patients with respect to normal controls. After 12 wk of lenalidomide treatment, all patients had an erythroid response. There was a significant increase in median RPS14 expression from baseline 0.01 (IQR 0.05–0.31) to 12 wk 204.71‐fold (2.86–446.32; P < 0.0001).Conclusions:  These observations in the patient setting support the importance of RPS14 in the pathogenesis of MDS with del(5q).


  • Iron chelation therapy associated with improvement of hematopoiesis in transfusion‐dependent patients

    by Esther Natalie Oliva, Francesca Ronco, Antonio Marino, Caterina Alati, Giulia Praticò, Francesco Nobile

    BACKGROUND: It is well known that iron overload may cause multiple organ failure. In chronically transfused patients, optimal iron chelation therapy is associated with reduced morbidity and mortality. Furthermore, chelation therapy has been associated with erythroid responses.STUDY DESIGN AND METHODS: Among chronically transfused adults affected by myeloproliferative neoplasms and treated with iron chelators, two case reports are described.CASE REPORT: A male adult patient with myelodysplastic syndrome (MDS) and a female adult with aplastic anemia (AA), both transfusion‐dependent, were treated with deferasirox, an oral iron chelator.RESULTS: A significant reduction in transfusion requirement was observed and was dependent on chelation therapy. The patient affected by AA also experienced a significant increase in hemoglobin levels. Minimal doses of deferasirox maintained the erythroid responses. Many mechanisms of action of the drug on erythropoiesis have been postulated. The early erythroid response seems to be independent of the removal of iron from deposits, per se, since the reduction of ferritin levels (a surrogate marker of iron deposits) below threshold levels occurs as a later event.CONCLUSION: Although there are few reports on erythroid responses in patients undergoing iron chelation therapy, they may give new insights in the pathogenesis of MDS and other myeloproliferative neoplasms. AA may benefit in terms of erythroid response. The findings in these cases underline the clinical importance of treating patients with iron overload. A survival benefit of chelation in patients with myeloproliferative neoplasms is still to be confirmed.